A Placebo-controlled, Multi-center, Randomized, Phase 2b Study to Evaluate the Efficacy and Safety of ORMD-0801 in Type 2 Diabetes Mellitus Patients With Inadequate Glycemic Control on Oral Therapy
Phase of Trial: Phase II
Latest Information Update: 26 Jul 2018
At a glance
- Drugs Insulin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Oramed Pharmaceuticals
- 12 May 2018 Planned initiation date changed from 1 Apr 2018 to 1 May 2018.
- 23 Apr 2018 Status changed from not yet recruiting to recruiting, as reported in an Oramed Pharmaceuticals media release.
- 12 Apr 2018 Planned initiation date changed from 1 Mar 2018 to 1 Apr 2018.